Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VOGLIMON-GM2
- Development stage
- Unknown
- Lead developer
- Learmont Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VOGLIMON-GM2 is a fixed-dose combination (FDC) pharmaceutical product marketed by Learmont Pharmaceuticals for the management of type 2 diabetes mellitus. It consists of three oral hypoglycemic agents: voglibose, glimepiride, and metformin. Voglibose is an alpha-glucosidase inhibitor that reduces postprandial blood glucose by delaying carbohydrate digestion and absorption in the small intestine. Glimepiride is a second-generation sulfonylurea that stimulates insulin secretion from pancreatic beta cells by inhibiting ATP-sensitive potassium channels. Metformin is a biguanide that decreases hepatic glucose production and improves peripheral insulin sensitivity. This triple combination is typically indicated for patients whose glycemic levels are not adequately controlled by dual therapy with metformin and a sulfonylurea.
- Brand names
- VOGLIMON-GM2VOGLIMON-GM-2VOGLIMON-GM 2
- Other names
- Voglibose + Glimepiride + Metformin
02
Targets
SUR1 (Sulfonylurea receptor 1)Sucrase-Isomaltase
Beyond the preview
Go deeper on VOGLIMON-GM2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VOGLIMON-GM2.